FDA will continue the evolution of its approach to rare disease drug development in PDUFA VI by further immersing its staff dedicated to the sector into the application process.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?